SVRA Savara Inc.
Healthcare$5.02-0.79%ClosedMarket Cap: $1.03B
As of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
7.22
P/S
0.00
EV/EBITDA
-7.66
DCF Value
$-0.00
FCF Yield
-10.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-87.2%
ROA
-58.4%
ROIC
-65.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-37.3M | $— |
| Q4 null | $0.00 | $-32.2M | $— |
| FY null | $0.00 | $-118.8M | $— |
| Q3 null | $0.00 | $-29.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2025-12-23Wells FargoOverweight
2025-12-18OppenheimerOutperform
2025-11-14CitizensMarket Outperform
2025-11-13JMP SecuritiesMarket Outperform
2025-10-23Trading Activity
Insider Trades
View AllLowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Lowrance David Lofficer: Chief Financial Officer
SellFri Mar 20
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.28
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.